Last checked at 
LONDON (Alliance News) - N4 Pharma PLC on Tuesday said it appointed John Chiplin as non-executive chair of the company with immediate effect.
Furthermore, the pharmaceutical firm appointed Chris Britten as non-executive director, while Non-Executive Paul Titley has decided to step down for personal reasons and David Templeton, formerly chair, will now serve as a part-time executive director.
Chiplin has significant operational, investment and transaction experience in the life science and technology industries, N$ Pharma said. He served as chief executive of three unnamed publicly listed software, biotechnology and cancer immunotherapy companies in the US.
He is currently a director of Scancell Holdings PLC and other life sciences businesses.
Britten is an experienced pharmaceutical executive and is currently head of M&A at Neuraxpharm, a privately-owned European CNS specialty pharmaceutical company.
N4 shares were trading 0.1% lower at 3.55 pence each.
